Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights
Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights
Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis
Phase 3 clinical trial of ZERVIATE in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China
U.S. prescriptions for VYZULTA
TM by 56% over Q3 2020
Q4 2020 net revenue of €5.8 million, full year 2020 net revenue of €8.9 million and cash of €47.8 million at December 31, 2020 January 20, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and financial highlights for Q4 2020 for Nicox SA and its subsidiaries (the Nicox Group ), as well as key expected value-inflection milestones in 2021.
Nicox s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China December 30, 2020 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Ocumension Therapeutics, has initiated a Phase 3 clinical trial in China with ZERVIATE
TM, the first and only topical ocular formulation of the antihistamine cetirizine, for the treatment of ocular itching associated with allergic conjunctivitis.
Gavin Spencer, Chief Business Officer at Nicox, said:
Our teams worked very closely to obtain the Chinese Investigative New Drug approval for this trial and we are pleased that Ocumension has been able to capitalize on that with a swift initiation of the trial. This Phase 3 trial, in addition to the data package used by the FDA for ZERVIATE in the United States, is expected to be sufficient to support a Chinese New Drug Application. The initiation of thi